104TE/2022 - Improvement of original antitumor compounds pharmacological parameters using targeted nanoshuttles designed for colorectal cancer modern approach
104TE/2022 – ONCOTARGET
PN – III – P1 – 1.1. – TE – 2021 – 1660
General description
Project Coordinator: University of Bucharest
Project Director: Lecturer Ph.D.Bianca Gălățeanu
Contact: bianca.galateanu@bio.unibuc.ro
Funding Agency: UEFISCDI
Project duration: 24 months (13.05.2022 – 12.05.2024)
Total budget: 450.000 RON
Recent statistics rank colorectal cancer (CRC) as the second cause of cancer-related deaths and third as incidence and highlight the emerging need to improve the currently available therapeutic approaches. In the context of increasing resistance and dose-limiting side effects to traditional chemotherapy, there is a real need for the development of novel therapies, thus improving the current clinical landscape and increasing patients’ survival chances. However, despite identifying novel potent anticancer agents, these exhibit inappropriate pharmacological parameters for subsequent administration. In this context, the present proposal aims to fine-tune the pharmacological profile of novel lanthanide complexes of quinolone derivatives (oxolinic acid, nalidixic acid, and difloxacin) by their entrapment in original HA-poly (DMAEMA) targeted drug-delivery systems approaching colorectal cancer management. More, the current proposal fits within the modern direction of drug repositioning by bringing the activity of ‘older’ drugs back into clinical use for purposes that are outside the scope of the original medical indication.
Project
Project Objectives
Objective 1
Compound selection and drug delivery safety assessment
OBJECTIVE 2
Investigation of human blood/HA-poly (DMAEMA) nanoparticles interaction
OBJECTIVE 3
Evaluation of LCQD drug delivery systems antitumor in vitro efficacy
OBJECTIVE 4
Investigation of LCQD drug delivery systems antitumor potential in vivo
Project Team
Dedication. Expertise. Passion.
Project Phases
Phase I
13.05.2022 - 31.12.2022
Phase II
01.01.2023 - 31.12.2023
Phase III
01.01.2024 - 12.05.2024
Dissemination
Stage I
-
1 ISI article published: ​​Maciuca, A.M., Munteanu, A.C., Mihaila, M., Badea, M., Olar, R., Nitulescu, G.M., Munteanu, C.V. and Uivarosi, V., 2022. A Study on Repositioning Nalidixic Acid via Lanthanide Complexation: Synthesis, Characterization, Cytotoxicity and DNA/Protein Binding Studies. Pharmaceuticals, 15(8), p.1010 - IF: 5.125
-
1 participation at an international conference: FITC labeled HA-poly (DMAEMA) nanoparticles internalization profile within HT-29 adenocarcinoma cells. Galateanu Bianca, Ginghina Octav, Zamfir Marius, Velonia Kelly, Hudita Ariana. Al 33-lea Congres Mondial IASGO, 28.09.2022 – 01.10.2022, Istanbul, Turcia – poster
-
3 participation at a national conference:
-
Modeling Colorectal Cancer: From Flat Biology to Next Generation 3D Models. Galateanu Bianca, Ginghina Octav, Zamfir Marius, Mardare Mara, Velonia Kelly, Hudita Ariana. A doua editie a Conferintei OncoHub, 21.09.2022 – 23.09.2022, Brasov, România – oral presentation
-
Effects of Metal Coordination on the Antioxidant and Cytotoxic Properties of the Natural Flavonoid Primuletin. Ticea Alexandra-Cristina, Ungurianu Anca, Margina Denisa, Mihaila Mirela, Hudita Ariana, Galateanu Bianca, Uivarosi Valentina. A doua editie a Conferintei OncoHub, 21.09.2022 – 23.09.2022, Brasov, România – oral presentation
-
In Vitro IC50 Dose Screening for Lanthanide Complexes with Nalidixic Acid for Their Prospective Use in Colorectal Cancer Therapy. Galateanu Bianca, Uivarosi Valentina, Ticea Alexandra-Cristina, Maciuca Ana-Madalina, Ginghina Octav, Mardare Mara, Tanase Bogdan Cosmin, Hudita Ariana. CONFER, 23.11.2022 – 26.11.2022, IaÈ™i, România – poster
-
Stage II
-
1 ISI article under evaluation;
-
4 participation at a international conference:
-
Familial Polyposis – the good, the bad and the ugly. Andrei Vacarasu, Marius Zamfir, Mardare Mara, Irina Bondoc, Dana Cernov, Theodor Comanica-Stinga, Razvan Iosifescu, Ariana Hudita, Bianca Galateanu, Alin Burlacu, Jeanina Valcea, Theodor Voiosu, Andrei Voiosu, Florin Grama, Maria Barbu, Bogdan Tanase, Laurentiu Simion, Octav Ginghina. 42nd Congress of the European Society of Surgical Oncology ESSO, 25 – 27 October 2023, Florence, Italy – poster presentation
-
FITC labeled HA-poly(DMAEMA) nanoparticles internalization profile within HT-29 adenocarcinoma cells. Bianca Galateanu, Octav Ginghina, Kelly Velonia, Ariana Hudita. The 5th Edtition of the International Conference of Material Research and Nanotechnology ICMRN, 20-21 April, 2023, Paris, France – poster presentation
-
Blood - HA - poly(DMAEMA) - nanoparticles interaction assessment for hemocompatibility validation. Ariana Hudita, Octav Ginghina, Kelly Velonia, Bianca Galateanu,. The 5th Edtition of the International Conference of Material Research and Nanotechnology ICMRN, 20-21 April, 2023, Paris, France – poster presentation
-
La(Nal)3 loaded PDMAEMA NPs induce HT-29 adenocarcinoma cells apoptosis in vitro. Bianca Galateanu, Alexandra Cowell, Valentina Uivarosi, Mirto Charitaki, Kelly Velonia, Ariana Hudita, The Anual International Conference of the Romanian Society of Biochemistry and Molecular Biology, 13-15 September 2023, Cluj Napoca, Romania– poster presentation
-
-
1 participation at a national conference:
-
Optimization of a flow cytometry protocol for tumor microenvironment characterization. Bianca Galateanu, Ariana Hudita, The 3rd Edition of the OncoHub Conference - Connecting Scientists and Physicians for Next Generation Cancer Management, 20-22 September 2023, Bucharest, Romania–oral presentation
-
